{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:04:12Z","timestamp":1790111052561,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10549-026-08086-1","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:05:40Z","timestamp":1790107540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ki-67 expression and rates of pathologic complete response in T1cN0M0 triple-negative breast cancer: a national cancer database analysis"],"prefix":"10.1007","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-8299","authenticated-orcid":false,"given":"Andrew","family":"Venardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Shojaeian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin R.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishrar","family":"Shaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambika","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Santa-Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olutayo","family":"Sogunro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"8086_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"8086_CR2","doi-asserted-by":"publisher","first-page":"115545","DOI":"10.1016\/j.bcp.2023.115545","volume":"212","author":"AM Karim","year":"2023","unstructured":"Karim AM, Eun Kwon J, Ali T, Jang J, Ullah I, Lee YG, Park DW, Park J, Jeang JW, Kang SC (2023) Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. Biochem Pharmacol 212:115545. https:\/\/doi.org\/10.1016\/j.bcp.2023.115545","journal-title":"Biochem Pharmacol"},{"key":"8086_CR3","doi-asserted-by":"publisher","first-page":"836417","DOI":"10.3389\/fmolb.2022.836417","volume":"9","author":"NM Almansour","year":"2022","unstructured":"Almansour NM (2022) Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Front Mol Biosci 9:836417. https:\/\/doi.org\/10.3389\/fmolb.2022.836417","journal-title":"Front Mol Biosci"},{"key":"8086_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/PPO.0000000000000498","volume":"27","author":"A Marra","year":"2021","unstructured":"Marra A, Curigliano G (2021) Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy. Cancer J 27:41\u201349. https:\/\/doi.org\/10.1097\/PPO.0000000000000498","journal-title":"Cancer J"},{"key":"8086_CR5","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.clbc.2025.05.011","volume":"25","author":"JD Anampa","year":"2025","unstructured":"Anampa JD, Soto AA, Lin S, Bernal AM, Xue X, Oktay MH (2025) Use and Benefit of Neoadjuvant Versus Adjuvant Chemotherapy in Node-Negative, T1 Triple Negative Breast Cancer. Clin Breast Cancer 25:979\u2013989. https:\/\/doi.org\/10.1016\/j.clbc.2025.05.011","journal-title":"Clin Breast Cancer"},{"key":"8086_CR6","unstructured":"National Comprehensive Cancer Network (2026) NCCN clinical practice guidelines in oncology: breast cancer. Version 4.2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 1 April 2026"},{"key":"8086_CR7","doi-asserted-by":"publisher","first-page":"e520666","DOI":"10.1200\/EDBK-26-520666","volume":"46","author":"Dame","year":"2026","unstructured":"Dame, Idossa et al (2026) Stage I Triple-Negative Breast Cancer: Moving from One-Size-Fits-All to a Personalized Approach. Am Soc Clin Oncol Educ Book 46:e520666. https:\/\/doi.org\/10.1200\/EDBK-26-520666","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"8086_CR8","doi-asserted-by":"publisher","first-page":"7026","DOI":"10.1245\/s10434-023-13977-4","volume":"30","author":"K Huang","year":"2023","unstructured":"Huang K, Jakub J, Gabriel E, Moreno-Aspitia A, McLaughlin S (2023) Overall Survival Following Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Clinically Node Negative T1 Triple Negative Breast Cancer. Ann Surg Oncol 30:7026\u20137035. https:\/\/doi.org\/10.1245\/s10434-023-13977-4","journal-title":"Ann Surg Oncol"},{"key":"8086_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s13193-024-02032-7","volume":"15","author":"R Raxith Sringeri","year":"2024","unstructured":"Raxith Sringeri R (2024) Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: Impact on Early Stage and Outcomes-Comprehensive Review. Indian J Surg Oncol 15:501\u2013508. https:\/\/doi.org\/10.1007\/s13193-024-02032-7","journal-title":"Indian J Surg Oncol"},{"key":"8086_CR10","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1158\/0008-5472.CAN-20-1792","volume":"80","author":"M Huang","year":"2020","unstructured":"Huang M, O\u2019Shaughnessy J, Zhao J, Haiderali A, Cort\u00e9s J, Ramsey SD, Briggs A, Hu P, Karantza V, Aktan G, Qi CZ, Gu C, Xie J, Yuan M, Cook J, Untch M, Schmid P, Fasching PA (2020) Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. Cancer Res 80:5427\u20135434. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1792","journal-title":"Cancer Res"},{"key":"8086_CR11","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.3390\/cancers13174455","volume":"13","author":"MG Davey","year":"2021","unstructured":"Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ (2021) Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. Cancers (Basel) 13:4455. https:\/\/doi.org\/10.3390\/cancers13174455","journal-title":"Cancers (Basel)"},{"key":"8086_CR12","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.21037\/tcr-21-180","volume":"10","author":"G Zhang","year":"2021","unstructured":"Zhang G, Shi Z, Liu L, Yuan H, Pan Z, Li W, Tao Y, Huang Z, Huang X, Lin C (2021) The prognostic relevance of p53 and Ki-67 to chemotherapy sensitivity and prognosis in triple-negative breast cancer. Transl Cancer Res 10:1082\u20131087. https:\/\/doi.org\/10.21037\/tcr-21-180","journal-title":"Transl Cancer Res"},{"issue":"2","key":"8086_CR13","doi-asserted-by":"publisher","first-page":"R22","DOI":"10.1186\/bcr2834","volume":"13","author":"B Keam","year":"2011","unstructured":"Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13(2):R22. https:\/\/doi.org\/10.1186\/bcr2834. PMID: 21366896; PMCID: PMC3219180","journal-title":"Breast Cancer Res"},{"key":"8086_CR14","doi-asserted-by":"publisher","first-page":"30091","DOI":"10.1038\/srep30091","volume":"6","author":"RX Wang","year":"2016","unstructured":"Wang RX, Chen S, Jin X et al (2016) Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. Sci Rep 6:30091. https:\/\/doi.org\/10.1038\/srep30091","journal-title":"Sci Rep"},{"key":"8086_CR15","doi-asserted-by":"publisher","first-page":"1269971","DOI":"10.3389\/fonc.2023.1269971","volume":"13","author":"SJ Lee","year":"2023","unstructured":"Lee SJ, Go J, Ahn BS, Ahn JH, Kim JY, Park HS, Kim SI, Park B-W, Park S (2023) Lymphovascular invasion is an independent prognostic factor in breast cancer irrespective of axillary node metastasis and molecular subtypes. Front Oncol 13:1269971. https:\/\/doi.org\/10.3389\/fonc.2023.1269971","journal-title":"Front Oncol"},{"key":"8086_CR16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3857\/roj.2017.00416","volume":"35","author":"KJ Ahn","year":"2017","unstructured":"Ahn KJ, Park J, Choi Y (2017) Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer after surgery. Radiat Oncol J 35:332\u2013339. https:\/\/doi.org\/10.3857\/roj.2017.00416","journal-title":"Radiat Oncol J"},{"key":"8086_CR17","doi-asserted-by":"publisher","first-page":"12564","DOI":"10.1200\/JCO.2024.42.16_suppl.e12564","volume":"42","author":"Shuwen","year":"2024","unstructured":"Shuwen, Lin et al (2024) Short-term and long-term survival outcomes in patients with invasive lobular carcinoma vs. invasive ductal carcinoma of the breast. J Clin Oncol 42:12564\u201312564. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e12564","journal-title":"J Clin Oncol"},{"key":"8086_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.breast.2021.06.011","volume":"59","author":"F Conforti","year":"2021","unstructured":"Conforti F, Pala L, Pagan E, Rocco EG, Bagnardi V, Montagna E, Peruzzotti G, De Pas T, Fumagalli C, Pileggi S, Pesenti C, Marchini S, Corso G, Marchio\u2019 C, Sapino A, Graffeo R, Collet L, Aftimos P, Sotiriou C, Piccart M, Gelber RD, Viale G, Colleoni M, Goldhirsch A (2021) Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. Breast 59:94\u2013101. https:\/\/doi.org\/10.1016\/j.breast.2021.06.011","journal-title":"Breast"},{"key":"8086_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s10549-025-07862-9","volume":"215","author":"J Nyqvist-Streng","year":"2025","unstructured":"Nyqvist-Streng J, Chamalidou C, Kovacs A, Parris TZ (2025) Worse survival despite indolent features for triple-negative invasive lobular carcinoma: a Swedish nationwide registry-based study. Breast Cancer Res Treat 215:12. https:\/\/doi.org\/10.1007\/s10549-025-07862-9","journal-title":"Breast Cancer Res Treat"},{"key":"8086_CR20","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3390\/healthcare11050746","volume":"11","author":"AM Pereslucha","year":"2023","unstructured":"Pereslucha AM, Wenger DM, Morris MF, Aydi ZB (2023) Invasive Lobular Carcinoma: A Review of Imaging Modalities with Special Focus on Pathology Concordance. Healthc (Basel) 11:746. https:\/\/doi.org\/10.3390\/healthcare11050746","journal-title":"Healthc (Basel)"},{"key":"8086_CR21","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-10455-7","author":"D Cocco","year":"2021","unstructured":"Cocco D, ElSherif A, Wright MD, Dempster MS, Kruse ML, Li H, Valente SA (2021) Invasive lobular breast cancer: data to support surgical decision making. Ann Surg Oncol 28:5723\u20135729. https:\/\/doi.org\/10.1245\/s10434-021-10455-7"},{"key":"8086_CR22","doi-asserted-by":"publisher","first-page":"103877","DOI":"10.1016\/j.breast.2025.103877","volume":"79","author":"YZ Zheng","year":"2025","unstructured":"Zheng YZ, Ying JQ, Wu TT, Su YH, Wang OC (2025) Comparative survival outcomes of neoadjuvant and adjuvant therapy in patients with T1c, node-negative, triple-negative breast cancer: A population-based analysis. Breast 79:103877. https:\/\/doi.org\/10.1016\/j.breast.2025.103877","journal-title":"Breast"},{"key":"8086_CR23","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1245\/s10434-025-17285-x","volume":"32","author":"A Murillo","year":"2025","unstructured":"Murillo A, Romatoski KS, Chung SH, Davis ES, Sawhney VS, Kenzik K, Ng SC, Tseng JF, Sachs TE (2025) Adjusting for Population Differences in the National Cancer Database to Better Represent United States Cancer Cases: A Reference Tool for Researchers. Ann Surg Oncol 32:4604\u20134615. https:\/\/doi.org\/10.1245\/s10434-025-17285-x","journal-title":"Ann Surg Oncol"},{"key":"8086_CR24","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","volume":"3","author":"DJ Boffa","year":"2016","unstructured":"Boffa DJ, Rosen JE, Mallin K, Loomis A, Gay G, Palis B, Thoburn K, Gress D, McKellar DP, Shulman LN, Facktor MA, Winchester DP (2016) Using the National Cancer Database for Outcomes Research: A Review. JAMA Oncol 3:1722\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6905","journal-title":"JAMA Oncol"},{"key":"8086_CR25","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1200\/JCO.22.00069","volume":"40","author":"Fabrice","year":"2022","unstructured":"Fabrice, Andre et al (2022) Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. J Clin Oncol 40:1816\u20131837. https:\/\/doi.org\/10.1200\/JCO.22.00069","journal-title":"J Clin Oncol"},{"key":"8086_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.esmoop.2025.105923","volume":"10","author":"M de Graaf","year":"2025","unstructured":"de Graaf M, Gielen R, Balduzzi S et al (2025) Pathological Complete Response and Survival after Neoadjuvant Chemotherapy in Patients with Stage I TNBC: a Registry-Based Study. ESMO Open 10:12. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105923","journal-title":"ESMO Open"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08086-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08086-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08086-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:05:42Z","timestamp":1790107542000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08086-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8086"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08086-1","relation":{"references":[{"id-type":"doi","id":"10.1245\/s10434-021-10455-7","asserted-by":"subject"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"6 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Johns Hopkins Institutional Review Board (IRB00363497).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the retrospective nature of the study using population-based data, the requirement for written informed consent was waived.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"21"}}